Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in three major healthcare investor conferences this November. The company will present at Guggenheim's Inaugural Healthcare Innovation Conference (Nov 13), the Stifel 2024 Healthcare Conference (Nov 18), and the Jefferies London Healthcare Conference (Nov 20). Live audio webcasts and replays will be accessible through Spyre's investor events website.

News Market Reaction – SYRE

-4.77%

-4.77% Session move

In the trading session that priced this news, SYRE declined 4.77%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Oct. 30, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in the following upcoming investor conferences:

Event: Guggenheim's Inaugural Healthcare Innovation Conference
Date: Wednesday, November 13, 2024
Time: 2:30pm ET

Event: Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Time: 1:15 pm ET

Event: Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
Time: 10:30 am GMT

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.

Follow Spyre Therapeutics on social media: @spyretx and LinkedIn

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-november-investor-conferences-302291439.html

SOURCE Spyre Therapeutics, Inc.

FAQ

What investor conferences will Spyre Therapeutics (SYRE) attend in November 2024?

Spyre Therapeutics will participate in three conferences: Guggenheim's Inaugural Healthcare Innovation Conference on Nov 13, Stifel 2024 Healthcare Conference on Nov 18, and Jefferies London Healthcare Conference on Nov 20.

When is Spyre Therapeutics (SYRE) presenting at the Guggenheim Healthcare Conference 2024?

Spyre Therapeutics will present at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 2:30pm ET.

How can investors access Spyre Therapeutics (SYRE) conference presentations?

Investors can access live audio webcasts and replays of the presentations through Spyre's investor events website at ir.spyre.com/events-and-presentations.

What is the main therapeutic focus of Spyre Therapeutics (SYRE)?

Spyre Therapeutics focuses on developing treatments for Inflammatory Bowel Disease (IBD) using antibody engineering, rational therapeutic combinations, and precision medicine approaches.